MGDSX Performance — NYLI Growth Allocation Fund, SIMPLE Class
Data updated: 2026-09-23
MGDSX returned +9.39% year to date and +16.94% over one year to Jul 2026. Annualised returns are +11.77% over 3 years and +6.37% over 5 years. Against its Alternative category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $140, against $168 for the category, and to $117 over one year, against $108. Volatility over the past three years was 10.97% a year. In the 12 months to Jul 2026 the fund lost a net $27.0M, and assets reached $893.99M.
MGDSX Growth of $100
What $100 invested in NYLI Growth Allocation Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Alternative category average over the same months.
| Period | MGDSX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $117 | $108 |
| 3 years (Aug 2023 – Jul 2026) | $140 | $168 |
| 5 years (Aug 2021 – Jul 2026) | $136 | $159 |
| Since data start (Sep 2020 – Jul 2026) | $166 | $179 |
MGDSX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.39% |
| 1 year | +16.94% |
| 3 years (annualised) | +11.77% |
| 5 years (annualised) | +6.37% |
MGDSX Annual Returns
Calendar-year total returns of NYLI Growth Allocation Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +9.39% |
| 2025 | +12.14% |
| 2024 | +9.84% |
| 2023 | +14.60% |
| 2022 | −14.98% |
| 2021 | +15.92% |
| 2020 (Sep–Dec) | +8.89% |
MGDSX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.5% | +1.3% | −5.5% | +7.8% | +3.6% | +0.9% | −1.1% | — | — | — | — | — |
| 2025 | +3.1% | −1.9% | −3.8% | +0.1% | +3.9% | +3.2% | +0.3% | +2.5% | +1.8% | +1.1% | +0.8% | +0.5% |
| 2024 | +0.3% | +2.8% | +2.6% | −3.8% | +3.0% | +1.1% | +2.5% | +1.4% | +1.5% | −2.0% | +4.9% | −4.4% |
| 2023 | +6.0% | −2.2% | +0.2% | +0.4% | −1.5% | +4.7% | +2.8% | −2.1% | −3.8% | −2.7% | +7.5% | +5.2% |
| 2022 | −5.0% | −1.7% | +1.7% | −6.6% | +0.3% | −7.7% | +6.9% | −3.4% | −7.9% | +7.1% | +5.7% | −4.0% |
| 2021 | −0.4% | +2.8% | +2.4% | +3.7% | +1.2% | +0.5% | +1.0% | +1.8% | −3.5% | +4.4% | −2.4% | +3.6% |
| 2020 | — | — | — | — | — | — | — | — | −2.8% | −1.9% | +9.8% | +4.0% |
MGDSX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 10.97%
- 3-year Sharpe ratio: 0.66 (vs 4.5% risk-free rate)
- Best month: +7.81% (Apr 2026)
- Worst month: −5.48% (Mar 2026)
MGDSX Fund Flows
Monthly money in and out of NYLI Growth Allocation Fund, from SEC Form N-PORT.
- 12-month net flow: −$27.0M
- 12-month gross sales (incl. reinvestments): $116.2M
- Sales ÷ redemptions: 0.81×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $3.8M | $10.3M | −$6.5M |
| Jun 2026 | $14.9M | $20.5M | −$5.6M |
| May 2026 | $4.1M | $10.5M | −$6.4M |
| Apr 2026 | $5.0M | $9.4M | −$4.4M |
| Mar 2026 | $6.8M | $12.4M | −$5.6M |
| Feb 2026 | $4.2M | $10.9M | −$6.7M |
| Jan 2026 | $4.6M | $11.0M | −$6.4M |
| Dec 2025 | $48.1M | $14.1M | $34.0M |
| Nov 2025 | $3.9M | $8.8M | −$4.9M |
| Oct 2025 | $4.3M | $8.8M | −$4.5M |
| Sep 2025 | $12.8M | $17.1M | −$4.3M |
| Aug 2025 | $3.8M | $9.5M | −$5.6M |
MGDSX Assets Under Management
Net assets of NYLI Growth Allocation Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $893.99M |
| 2026-04-30 | $882.31M |
| 2026-01-31 | $870.80M |
| 2025-10-31 | $855.66M |
| 2025-07-31 | $824.64M |
| 2025-04-30 | $786.88M |
| 2025-01-31 | $853.06M |
| 2024-10-31 | $841.25M |
| 2024-07-31 | $851.25M |
| 2024-04-30 | $815.87M |
| 2024-01-31 | $821.15M |
| 2023-10-31 | $734.70M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.